#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating pregnant and postpartum people with HIV need evidence on concurrent alcohol and cannabis use to assess risks to fetal development, maternal health, and antiretroviral adherence, as these substances may interact with HIV medications and complicate pregnancy outcomes. This research directly informs counseling practices and harm reduction strategies for a vulnerable population where substance use patterns may differ from general obstetric populations. Identifying clinical and obstetric characteristics associated with use enables targeted interventions that balance reproductive autonomy with protection of maternal and fetal health in HIV-positive patients.
This study examines the prevalence and clinical correlates of alcohol and cannabis use during pregnancy and the postpartum period among people with HIV, a population at higher risk for substance use and adverse perinatal outcomes. Understanding the patterns and characteristics of concurrent alcohol and cannabis use in this vulnerable group is critical because both substances can compromise antiretroviral therapy adherence, increase transmission risk, and adversely affect fetal development and infant health outcomes. The findings provide clinicians with evidence-based insights into screening practices and intervention opportunities for pregnant and postpartum patients with HIV who may use these substances. For practitioners caring for this population, recognizing the interconnections between HIV management, substance use, and reproductive health enables more comprehensive and nonjudgmental counseling about risks and safer alternatives. Clinicians should incorporate routine, validated screening for alcohol and cannabis use into prenatal and postpartum care for all patients with HIV, using positive results as an entry point for evidence-based counseling and treatment referral rather than stigmatizing care.
“This observational study gives us valuable descriptive information about substance use patterns in a specific population, but we need to be careful not to overinterpret associations as causation, especially when we’re talking about pregnancy outcomes where so many factors interact. What I take from this is that pregnant people with HIV who use alcohol or cannabis may need more integrated, nonjudgmental screening and support, but we still lack the robust prospective data to make specific clinical recommendations about cannabis in this setting.”
💊 Substance use during pregnancy and postpartum in people with HIV represents a complex intersection of maternal health, fetal development, and HIV disease management that warrants careful clinical attention. While this research highlights the need to characterize patterns of alcohol and cannabis use in this population, providers should recognize that pregnancy outcomes in HIV-positive individuals are influenced by multiple overlapping factors including antiretroviral adherence, viral suppression, nutritional status, and psychosocial stressors—all of which may confound associations between substance use and adverse outcomes. Cannabis use in particular presents a clinical dilemma given limited evidence on prenatal safety and concerns about impaired judgment affecting medication adherence and prenatal care engagement, while postpartum use may affect breastfeeding decisions and parenting capacity in ways that differ from general obstetric populations. Rather than focusing narrowly on substance use, clinicians caring for pregnant and postpartum patients with HIV should implement comprehensive
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
